Related Experiment Video
Updated: May 14, 2026
05:44
Modeling Multiple Sclerosis in the Two Sexes: MOG35-55-Induced Experimental Autoimmune Encephalomyelitis
Published on: October 13, 2023
Multiple sclerosis: does Nogo play a role?
Jae Young Lee1, Steven Petratos
1Monash Immunology and Stem Cell Laboratories, Monash University, Clayton, Victoria, Australia.
Summary
Nogo-A protein inhibits nerve regrowth and is found in multiple sclerosis lesions. Targeting Nogo signaling shows potential for neuroprotection in MS, but complexities require further investigation.
Area of Science:
- Neurobiology
- Neuroimmunology
- Clinical Neurology
Background:
- Nogo-A is an integral myelin protein known to inhibit neurite outgrowth.
- Nogo-A signals via Nogo receptor 1 (NgR1) in complex with p75(NTR), TROY, and LINGO-1.
- Both Nogo-A and NgR1 are present in multiple sclerosis (MS) lesions, implicating Nogo signaling in disease pathology.
Purpose of the Study:
- To systematically review the complexities of Nogo signaling in the context of MS.
- To explore the potential of targeting Nogo signaling for neuroprotective therapies in MS.
Main Methods:
- Literature review of fundamental neurobiology and clinical studies on Nogo-A and NgR1.
- Analysis of the role of Nogo signaling in animal models of MS.
- Examination of the impact of inflammatory infiltration on Nogo signaling components.
Main Results:
- Nogo signaling is implicated in axonal retraction and is present in MS lesions.
- Therapeutic strategies targeting Nogo signaling in MS models are under debate.
- Discrepancies in animal model results may stem from ligand variability and signaling molecule localization.
Conclusions:
- Understanding the intricate Nogo signaling pathway is crucial for developing effective neuroprotective therapies for MS.
- Further research is needed to clarify the precise role and therapeutic targeting of Nogo signaling in MS progression.
Related Concept Videos
01:19Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
01:22Myasthenia Gravis ll: Pathophysiology
The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
01:28Disorders of the Nervous Tissue
Nervous tissue is a vital component of the human body's communication system, enabling us to perceive and respond to stimuli. However, like all other tissues, it is vulnerable to disorders and diseases that can significantly impact our neurological functioning.
Homeostatic Imbalances:
Alzheimer's disease manifests as a gradual decline in memory and cognitive abilities, attributed to the buildup of amyloid plaques and neurofibrillary tangles in the brain.
Parkinson's disease arises from the...
Homeostatic Imbalances:
Alzheimer's disease manifests as a gradual decline in memory and cognitive abilities, attributed to the buildup of amyloid plaques and neurofibrillary tangles in the brain.
Parkinson's disease arises from the...
01:25Secondary Spinal Cord Injury llI: Pathophysiology
Early Ischemia and Ionic ImbalanceWithin minutes of spinal cord injury, a secondary cascade begins, progressing over hours to weeks. Vascular damage reduces blood flow, causing ischemia and mitochondrial dysfunction. ATP depletion leads to ion pump failure, membrane depolarization, sodium influx, potassium efflux, and water accumulation, resulting in cellular swelling. Increased intracellular calcium further disrupts mitochondria and accelerates cellular injury.Excitotoxicity and Neuronal...
01:14Spinal Cord Injury ll: Pathophysiology
Spinal cord injury progresses through two interconnected phases: primary injury and secondary injury.Primary InjuryPrimary injury happens at the moment of trauma and involves immediate mechanical damage to the spinal cord.Compression happens when broken vertebrae, herniated discs, or accumulating blood (such as a hematoma) press directly against the spinal cord, distorting its normal shape and function. In cases of contusion, the cord is bruised by a blunt force (like penetrating injuries or...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...